Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft.
Plasma cell-rich acute rejection (PCAR) is associated with poor allograft outcome in renal transplantation. Previous studies report a graft half-life of six months after a single PCAR episode. However, the management of this condition is unclear. Intravenous immunoglobulin (IVIG) therapy, by virtue of its immunomodulating properties, and its influence on B-cell maturation into plasma cells, may be a good candidate for reversing this type of rejection. We report four episodes of PCAR in two patients who responded well to IVIG with improvement in renal function.
Adrogue
Horacio E
HE
Nephrology Section, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA. horacioa@bcm.edu
Soltero
Liliana
L
Land
Geoffrey A
GA
Ramanathan
Venkataraman
V
Truong
Luan D
LD
Suki
Wadi N
WN
D000328:Adult; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010950:Plasma Cells / Q000473:pathology*; D014184:Transplantation, Homologous
D016756:Immunoglobulins, Intravenous